Stempeucel-OA® Demonstrates Durable 24-Month Efficacy and Cartilage Preservation in Phase 3 Knee Osteoarthritis Study

▴ Stempeutics, a leader in allogeneic cellular medicines
Peer-reviewed results published in Osteoarthritis and Cartilage Open show significant improvements in pain, function, and structural outcomes versus placebo.

India | January 20, 2026: Stempeutics, a leader in allogeneic cellular medicines for inflammatory diseases, announced the publication of 24-month efficacy and safety results from its Phase 3, randomized, double-blind, placebo-controlled clinical study of Stempeucel-OA® in knee osteoarthritis. The results were published in Osteoarthritis and Cartilage Open, a peer-reviewed international journal.

 

At 24 months, a single intra-articular injection of Stempeucel-OA® demonstrated statistically significant and durable improvements in clinical outcomes compared with placebo, supporting the therapy’s potential as a disease-modifying treatment for knee osteoarthritis.

 

Key 24-Month Findings

  • Pain and function: Statistically significant improvement in the WOMAC composite index and all WOMAC sub-scores in the Stempeucel-OA® group versus placebo (p < 0.0001).

 

  • Cartilage preservation: T2 mapping showed no worsening of cartilage in the medial femorotibial compartment in the Stempeucel-OA® group, while the placebo group demonstrated progressive degeneration (p < 0.0001). Cartilage volume increased in the Stempeucel-OA® group over time.

 

  • Biomarker response: Urinary C-terminal cross-linked telopeptide of type II collagen (uCTX-II), a biomarker of cartilage degradation, decreased significantly in the Stempeucel-OA® group and increased in the placebo group at Days 90 and 730 (p < 0.0001).

 

Twelve-month results from the same Phase 3 study were previously published in the American Journal of Sports Medicine (2023;51(9):2254-2266).

 

In India, Stempeucel-OA® is commercially available through marketing partnerships with Alkem Laboratories under the brand name StemOne® and with Cipla under the brand name CiploStem®, and is accessible across major hospitals nationwide.

 

Dr. Joe Joseph Cherian, MS, Professor and Head of the Department of Orthopaedics at St. John’s Medical College Hospital, Bangalore, and a Phase 3 investigator, commented:

“The two-year follow-up data underscore the potential of allogeneic cellular therapy to address key unmet needs in knee osteoarthritis, particularly in younger patients where existing treatments provide only transient symptom relief without altering disease progression. Based on the Phase 3 data, Stempeucel-OA® demonstrates durable pain reduction, improvements in physical function and quality of life, and the potential to preserve cartilage and slow disease progression in patients with Grade 2 and Grade 3 osteoarthritis as defined by Kellgren–Lawrence criteria.”

 

Dr. Nikhil Verma, MD, Rush University Medical Center, Chicago, added:

“These results may usher in new directions for the field of cell-based regenerative therapies over the coming decade.” Stempeutics has further characterized the potency of Stempeucel-OA® through its ability to secrete pro-chondrogenic factors, including thrombospondin-2 (TSP-2). TSP-2 is an extracellular matrix protein that plays a critical role in chondrogenic differentiation and in stimulating endogenous chondroprogenitor cells. Given that osteoarthritis is fundamentally driven by progressive cartilage loss, the presence of these factors in the MSC secretome provides a plausible mechanistic link to the observed clinical and structural outcomes.

 

Dr. Pawan Gupta, President, Medical & Regulatory Affairs at Stempeutics, stated:

“Osteoarthritis is one of the most prevalent and debilitating conditions associated with aging, with increasing incidence driven in part by rising obesity rates. In India alone, an estimated 30 million individuals are affected. Current treatment options largely focus on temporary pain relief and inflammation control without altering disease progression. Stempeucel-OA® has the potential to deliver durable symptom improvement while preserving cartilage and slowing disease progression in patients with radiographic Grade 2 and Grade 3 osteoarthritis.”

 

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026